Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System

NCT05211336 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

14

Enrollment

NIH

Sponsor class

Conditions

Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)
Aggressive B-cell Lymphoma With Secondary Involvement of the CNS

Interventions

DRUG: Obinutuzumab
DRUG: Prednisone
DRUG: Lenalidomide
DRUG: Venetoclax
DRUG: Ibrutinib
DRUG: Acetaminophen
DRUG: Diphenhydramine
OTHER: Peg-filgrastim
DIAGNOSTIC_TEST: CT Scan (chest, abdomen, and pelvis)
DIAGNOSTIC_TEST: MRI
DIAGNOSTIC_TEST: 18f-FDG-PET
DIAGNOSTIC_TEST: PET
DIAGNOSTIC_TEST: Lumbar puncture/Ommaya tap
DIAGNOSTIC_TEST: Bone marrow aspiration/biopsy
COMBINATION_PRODUCT: EKG

Sponsor

National Cancer Institute (NCI)